Renal protective effect after administration of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients and chronic kidney disease with normoalbuminuria
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000040424
- Lead Sponsor
- Obihiro-Kosei General Hospital
- Brief Summary
21 were treated with SGLT2 group and 25 were treated with other antidiabetic medications control group. Although eGFR was significantly decreased at 1 year in the control group, the decline in eGFR was not observed in the SGLT2 group. The decrease in eGFR was significantly smaller in the SGLT2 group than in the control group. Additionally, multiple linear regression analysis showed that an initial dip was an independent factor associated with the worsening of renal function in the SGLT2 group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 46
Not provided
1)type 1 diabetes 2)taking glucagon-like peptide-1 receptor agonists for type 2 diabetes 3)endocrine disease 4)taking steroid or immunosuppressant for autoimmune disease 5)dialysis, transplantation 6)liver cirrhosis and malignancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to assess the clinical effectiveness of SGLT2is on renal function by analyzing the change in eGFR at 1 years after initiating SGLT2 inhibitor compare with that in conventional antidiabetic medication
- Secondary Outcome Measures
Name Time Method to investigate the variables associated with the change in eGFR at 1 years after initiating SGLT2 inhibitor